Abingworth, the international investment group dedicated to life sciences and healthcare, today announced the final closing of its £225m ($375m) fund, Abingworth Bioventures VI (ABV VI). ABV VI, Abingworth's 10th life sciences fund, exceeded its target of £200 million and invests in life sciences and healthcare both in Europe and the US.
The fund invests broadly across all stages of development including early and late-stage private deals, VIPEs (Venture Investments in Public Equities), venture growth and public equities. Investment size will range from £5 million to £20 million per investment in total after all rounds of financing. The majority of the funds came from existing investors.
ABV VI is expected to make 15-20 investments and has already closed on four deals:
Avedro (US), technology for corneal crosslinking
Avillion (UK), structured finance for late-stage drug development
eFFECTOR (US), novel targets for therapeutics with main focus on cancer
GenSight Biologics (France), gene therapy for ophthalmology
"We are delighted to have attracted strong support from such high-quality LPs," said Stephen Bunting, Managing Partner. "This is an exciting time to launch our new fund, deal flow is strong whilst the number of competitors has diminished and markets remain supportive."
Asante Capital Group LLP acted as placement agent for ABV VI. King & Wood Mallesons SJ Berwin acted as legal counsel.